GlassScriptPhysician profile
John F Yee
NPI 1407810856
$12,043.22
in general payments reported to CMS, 2019-2025
28 companies · $15.27 in 2025
The $15.27 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,615 · 2020: $1,532 · 2021: $1,596 · 2022: $1,872 · 2023: $2,385 · 2024: $2,028 · 2025: $15.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,427.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,399.62 | 2019-2024 | Descovy |
| Astrazeneca Pharmaceuticals LP | $1,682.58 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,229.56 | 2021-2024 | Vraylar, Linzess, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $989.08 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $950.08 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $708.32 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $664.66 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $379.29 | 2019-2022 | |
| Viiv Healthcare Company | $377.09 | 2022-2024 | Apretude |
| Astellas Pharma US INC | $328.06 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $286.04 | 2019-2024 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $252.33 | 2020-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $190.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.50 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.28 | 2021-2023 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $157.11 | 2019-2020 | |
| Amgen INC. | $147.63 | 2019-2020 | |
| Amarin Pharma, INC. | $146.38 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.78 | 2022-2024 | Caplyta |
| Lundbeck LLC | $143.27 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $136.87 | 2022-2023 | Quviviq |
| Allergan, INC. | $97.38 | 2019-2020 | |
| Shield Therapeutics INC | $85.78 | 2022-2024 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $58.94 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $42.51 | 2022 | |
| Merck Sharp & Dohme LLC | $39.89 | 2019-2020 | |
| Exact Sciences Corporation | $32.77 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.